1. Home
  2. HRMY vs PAR Comparison

HRMY vs PAR Comparison

Compare HRMY & PAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • PAR
  • Stock Information
  • Founded
  • HRMY 2017
  • PAR 1968
  • Country
  • HRMY United States
  • PAR United States
  • Employees
  • HRMY N/A
  • PAR 1585
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • PAR Office Equipment/Supplies/Services
  • Sector
  • HRMY Health Care
  • PAR Miscellaneous
  • Exchange
  • HRMY Nasdaq
  • PAR Nasdaq
  • Market Cap
  • HRMY 1.5B
  • PAR 1.6B
  • IPO Year
  • HRMY 2020
  • PAR N/A
  • Fundamental
  • Price
  • HRMY $31.40
  • PAR $38.58
  • Analyst Decision
  • HRMY Strong Buy
  • PAR Strong Buy
  • Analyst Count
  • HRMY 9
  • PAR 7
  • Target Price
  • HRMY $50.44
  • PAR $68.86
  • AVG Volume (30 Days)
  • HRMY 912.0K
  • PAR 801.8K
  • Earning Date
  • HRMY 11-04-2025
  • PAR 11-06-2025
  • Dividend Yield
  • HRMY N/A
  • PAR N/A
  • EPS Growth
  • HRMY 50.44
  • PAR N/A
  • EPS
  • HRMY 3.17
  • PAR N/A
  • Revenue
  • HRMY $825,944,000.00
  • PAR $440,451,000.00
  • Revenue This Year
  • HRMY $20.68
  • PAR $28.97
  • Revenue Next Year
  • HRMY $15.93
  • PAR $14.51
  • P/E Ratio
  • HRMY $9.92
  • PAR N/A
  • Revenue Growth
  • HRMY 21.13
  • PAR 39.88
  • 52 Week Low
  • HRMY $25.52
  • PAR $32.57
  • 52 Week High
  • HRMY $40.93
  • PAR $82.24
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 63.59
  • PAR 56.37
  • Support Level
  • HRMY $27.66
  • PAR $32.57
  • Resistance Level
  • HRMY $30.96
  • PAR $36.25
  • Average True Range (ATR)
  • HRMY 1.25
  • PAR 1.46
  • MACD
  • HRMY 0.54
  • PAR 0.43
  • Stochastic Oscillator
  • HRMY 92.89
  • PAR 94.21

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About PAR PAR Technology Corporation

PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.

Share on Social Networks: